In this Exclusive Interview transcript, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of four major Novo Nordisk studies and their implications.

In this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of four major Novo Nordisk studies and their implications.

In part 1 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the results of their Pioneer One Study, the first to report on oral semaglutide, and what it means for people with type 1 and type 2.

In part 2 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the standings of the oral GLP-1 drug and their work on another oral drug.

In part 3 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the results of the SUSTAIN-7 trial and their implications for diabetes patients.

In part 4 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the benefits of both an SGLT-2 and GLP-1 injectable, as found in the Dual 9 study.

In part 5 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the overall results of the Confirm real-world study.

In part 6, the conclusion of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the upcoming focus on treating obesity as well as an oral form of semaglutide.

Higher risks seen for obesity, type 2 diabetes, circulatory system diseases

Excess hospitalizations seen across life span with large burden of mental illness in young adulthood